



## Post Authorisation Assessments

### Rearguard 6% w/v Cutaneous Solution Vm 52127/5069

29 April 2025	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
12 March 2025	Change of Marketing Authorisation Holder from: Elanco Europe Ltd., Form 2, Bartley Way, Bartley Wood Business Park, Hook, RG27 9XA, United Kingdom to: Elanco GmbH, Heinz-Lohmann Strasse 4, Groden, D-27472 Cuxhaven, Germany.
20 October 2024	Change in the manufacturer of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier: -Introduction of a manufacturer of the active substance supported by an ASMF.
16 October 2020	Change in the address of the Marketing Authorisation Holder from Elanco Europe Ltd, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL, United Kingdom to Elanco Europe Ltd, Form 2, Bartley Way, Bartley Wood Business Park, Hook, RG27 9XA, United Kingdom.
05 June 2019	Change in the safety database of an existing pharmacovigilance system as described in the DDPS.
06 July 2017	Change in the name and address of a manufacturer of the finished product, also responsible for batch release.
07 March 2017	Introduction of a new pharmacovigilance system.
15 December 2015	Change of MAH holder and Distributor from Novartis Animal Health UK Ltd to Elanco Europe Ltd.
16 January 2012	Change in site of manufacture of the finished product. Replacement of an excipient. Reduction of batch size.
16 January 2012	Renewal.
14 July 2010	Change in legal category from POM-V to NFA-VPS.
29 February 2008	Changes to the SPC and product literature to bring them into line with new legislation.
29 February 2008	Change in legal category from POM to POM-V.
12 November 2007	Change of address of MAH and distributor.
25 July 2007	Change of address of a manufacturer of the finished product.
04 March 2005	Change in the container shape.
24 March 2004	Change to labelling.